![]() |
|
|
Vol. 289, Issue 1, 202-210, April 1999
Neuropharmacology Research Laboratories, Departments of
Pharmacology (Z.D.L., H.C.R., C.W.T., P.M.C.) and
Neurological
Sciences (Z.D.L., P.M.C.), Rush-Presbyterian-St. Luke's Medical
Center, Chicago, Illinois
Pramipexole (PPX) is a full intrinsic activity, direct-acting dopamine
(DA) agonist possessing 7-fold higher affinity for D3 than
for D2 receptors. It also is a potent antioxidant. PPX was
previously shown to be neuroprotective because it dose dependently attenuated the DA neuron loss produced by levodopa in mesencephalic cultures. Several different drugs with properties similar to PPX were
studied here to better understand the mechanism or mechanisms responsible for this neuroprotective effect. The
D3-preferring agonist 7-hydroxy-diphenylaminotetralin
(7-OH-DPAT) and the D3 antagonist U99194, respectively,
increased and decreased the neuroprotective effects of PPX in a
dose-dependent fashion. Addition of the selective D2
agonist U95666 or the D2/D3 antagonists
domperidone or raclopride did not affect PPX's neuroprotective effect.
Interestingly, 7-OH-DPAT by itself did not attenuate the DA neuron loss
produced by levodopa. However, when 7-OH-DPAT was combined with a low
dose of the antioxidants U101033E or
-tocopherol, the toxic effects
of levodopa were attenuated. Similar results were observed when the
D3-preferring agonist PD128,907 was studied. In addition,
media conditioned by exposure of mesencephalic cultures incubated with
all D3-preferring agonists studied was shown to enhance the
growth of DA neurons in freshly harvested recipient cultures
implicating a D3-mediated trophic activity in the
neuroprotective effect. These data suggest that PPX's neuroprotective actions in the levodopa toxicity model are a consequence of its combined actions as a D3 receptor agonist and an antioxidant.
This article has been cited by other articles:
![]() |
R. Danzeisen, B. Schwalenstoecker, F. Gillardon, E. Buerger, V. Krzykalla, K. Klinder, L. Schild, B. Hengerer, A. C. Ludolph, C. Dorner-Ciossek, et al. Targeted Antioxidative and Neuroprotective Properties of the Dopamine Agonist Pramipexole and Its Nondopaminergic Enantiomer SND919CL2x [(+)2-Amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole Dihydrochloride] J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 189 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. LeWitt Clinical trials of neuroprotection for Parkinson's disease Neurology, October 12, 2004; 63(7_suppl_2): S23 - S31. [Full Text] |
||||
![]() |
C. Zeng, D. Wang, Z. Yang, Z. Wang, L. D. Asico, C. S. Wilcox, G. M. Eisner, W. J. Welch, R. A. Felder, and P. A. Jose Dopamine D1 Receptor Augmentation of D3 Receptor Action in Rat Aortic or Mesenteric Vascular Smooth Muscles Hypertension, March 1, 2004; 43(3): 673 - 679. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Ahlskog Slowing Parkinson's disease progression: Recent dopamine agonist trials Neurology, February 11, 2003; 60(3): 381 - 389. [Abstract] [Full Text] [PDF] |
||||